Avai Bio Inc.

NASDAQ: AVAIInvestor Site →

Avai Bio is a biotechnology company focused on advancing therapeutics solutions through innovative research and development across the life sciences sector.

Overview | Avai Bio Inc.

Company News|Latest News, Press and Market Commentary

No Newswire posts found

Bloomberg|News

Schwab's Sonders on the Rise of Casino Culture in Markets
US-Iran Talks Stall After Hezbollah Rejects Truce
SpaceX Seeks to Raise $75 Billion in What Could Be Biggest IPO Ever
US Adds 172,000 Jobs in May Topping All Estimates
US-Iran Talks at a Standstill as Hezbollah Rejects Truce
Ray Dalio on US Debt, AI Bubble, Bond Markets
California in Focus as Six State Hold Primaries
SpaceX Said to Target $75 Billion in IPO at $135 Per Share
Former VP Mike Pence on Conservatism, AI, Donald Trump
BofA CEO Moynihan on Affordability, Lending and AI Spending
Fed Beige Book Shows Steady Employment, Higher Inflation
Bloomberg Global Credit Forum | Live From New York

CNBC|News

CrowdStrike CEO George Kurtz goes one-on-one with Jim Cramer
Jim Cramer: I fear SpaceX is losing so much money the stock could be a drain for some time
Palo Alto Networks CEO Nikesh Arora goes one-on-on with Jim Cramer
FedEx Freight CEO John Smith sits down with Jim Cramer
I wonder if we will say this is the era when Dell took over the computer space, says Jim Cramer
Applied Materials CEO Gary Dickerson: This is the greatest time in the history of our industry
Salesforce CEO Marc Benioff goes one-on-one with Jim Cramer
Jim Cramer breaks down the numbers behind SpaceX's valuation
Databricks CEO Ali Ghodsi: AI doesn't have an intelligence problem. It has a context problem
Jim Cramer on playing the waiting game in the market
FedEx CEO responds to Amazon Supply Chain Services announcement
The American consumer is unbelievably resilient, says Affirm CEO

Market Chart

Spotrate

Avai Bio Inc.

ExchangeNASDAQ
SymbolNASDAQ: AVAI

Avai Bio is a biotechnology company focused on advancing therapeutics solutions through innovative research and development across the life sciences sector.

Market Summary

1

Total NASDAQ Listings: 3,500+

2

Technology Weighting: ~55%

3

Average Market Cap: $8.5B

4

Growth Bias: Innovation-led companies

Industry Insights

1

Biotech companies focus on therapeutic innovation.

2

Clinical pipelines drive valuation.

3

Regulatory milestones are key catalysts.

4

Partnerships accelerate commercialization.

Industry Leaders

Apple

AAPL

Consumer electronics and ecosystem leader.

Microsoft

MSFT

Cloud, software, and enterprise platforms.

NVIDIA

NVDA

AI and GPU computing leader.

Amazon

AMZN

E-commerce and cloud computing giant.

Meta Platforms

META

Social platforms and AI initiatives.

Alphabet

GOOGL

Search, ads, and AI infrastructure.

Tesla

TSLA

EV and AI-driven mobility platform.

Broadcom

AVGO

Semiconductors and infrastructure software.

Costco Wholesale

COST

Membership retail and consumer leader.

PepsiCo

PEP

Global food and beverage company.

Sector Stocks

Replimune Group

REPL

Oncolytic immunotherapy development.

ORIC Pharmaceuticals

ORIC

Targeted cancer therapies.

Anixa Biosciences

ANIX

Cancer immunotherapy and vaccines.

ImmunityBio

IBRX

Cell-based immunotherapy platform.

Iovance Biotherapeutics

IOVA

Tumor-infiltrating lymphocyte therapies.

Precigen

PGEN

Gene and cell therapy platform.

Exelixis

EXEL

Cancer-focused biotech therapeutics.

Incyte

INCY

Oncology and inflammation treatments.

BridgeBio Pharma

BBIO

Genetic disease therapeutics.

Krystal Biotech

KRYS

Gene therapy innovation.

Kymera Therapeutics

KYMR

Targeted protein degradation platform.

Moderna

MRNA

mRNA-based therapeutics and vaccines.

Regeneron Pharmaceuticals

REGN

Biologic drug development leader.

Vertex Pharmaceuticals

VRTX

Genetic disease therapies.

BioMarin Pharmaceutical

BMRN

Rare disease treatments.

Alnylam Pharmaceuticals

ALNY

RNA interference therapeutics.

Trading Platforms